gefitinib has been researched along with Dyspnea in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Acquaviva, G; Brand, T; Brandes, AA; Cavallo, G; de Biase, D; Degli Esposti, R; Di Battista, M; Genestreti, G; Pession, A; Tallini, G; Visani, M | 1 |
Chang, CY; Chang, SC; Chang, SJ; Chen, CY; Kuo, LC; Lai, YC; Liu, YC; Yu, CJ; Yuan, MK | 1 |
Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC | 1 |
Choe, JK; Cogswell, J; Kasimis, B; Nagaria, NC | 1 |
Fukuda, M; Kitazaki, T; Kohno, S; Soda, H | 1 |
Gatzemeier, U; Reck, M | 1 |
Ceribelli, A; Cognetti, F; Gelibter, A; Milella, M; Moscetti, L; Pollera, CF; Sperduti, I | 1 |
3 trial(s) available for gefitinib and Dyspnea
Article | Year |
---|---|
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy | 2013 |
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Dyspnea; Female; Follow-Up Studies; Gefitinib; Health Status; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Function Tests; Retrospective Studies; Sex Factors; Survival Analysis; Treatment Outcome | 2005 |
Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Constipation; Disease Progression; Dyspnea; Fatigue; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2005 |
4 other study(ies) available for gefitinib and Dyspnea
Article | Year |
---|---|
Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.
Topics: Adenocarcinoma; Aged; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Dyspnea; ErbB Receptors; Exons; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines | 2017 |
Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Female; Gefitinib; Hospital Mortality; Humans; Hypoxia; Incidence; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Taiwan | 2013 |
Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Pulmonary Fibrosis; Quinazolines | 2005 |
Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Dyspnea; Female; Gefitinib; Humans; Lung Neoplasms; Mucins; Quinazolines | 2005 |